1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsVirginia Assistive Technology Loan Fund Authority (Virginia ATF) is sponsored by Virginia Department for Aging and Rehabilitative Services (DARS). Provides low-interest loans to individuals with disabilities in Virginia for purchasing assistive technology devices and services.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Individuals with disabilities in Virginia. Confirm the full requirements in the official notice before applying.
The current listing shows up to $35,000. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Virginia Assistive Technology Loan Fund Authority (Virginia ATF) is funded by Virginia Department for Aging and Rehabilitative Services (DARS). Verify program details on the funder's official page before applying.
This opportunity targets applicants in Virginia. If your organization operates elsewhere, check the official notice for location requirements.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
The AFID Infrastructure Grant program closes October 30, 2026. Awards top out at $50,000, they are reimbursable, and only a political subdivision can apply. The August round put $507,000 into 14 projects at an average of about $36,000.
Read articleSeven research teams will run the first clinical trials aimed at extending human healthspan under ARPA-H PROSPR contracts worth up to $144M. The milestone-based contract model breaks every convention of federal biomedical funding.
Read articleARPA-H PROSPR program funds seven research teams up to $144M to develop the first clinical trials targeting biological aging itself, testing rapamycin analogs, semaglutide, and retrotransposon inhibitors.
Read article